# Avista Pharma Solutions, Inc. dba Cambrex – FDA Inspection, Jul 17, 2020

Source: https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/ee45f26b-b044-435f-9d45-4363448c47de
Source feed: FDA_Inspections

> FDA inspection 1128465 of Avista Pharma Solutions, Inc. dba Cambrex, July 17, 2020. Classification: No Action Indicated (NAI). 3 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1128465
- Company Name: Avista Pharma Solutions, Inc. dba Cambrex
- Inspection Date: 2020-07-17
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- [FDA Inspection 1277419 - 2025-07-03](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc-dba-cambrex/8a4208ef-dcad-47c0-9bbd-2ab3cdc26b19)
- FDA Inspection 805222 - 2012-10-30
- FDA Inspection 636454 - 2009-10-09

Company: https://www.keypedia.com/companies/avista-pharma-solutions-inc-dba-cambrex/56214bca-3cc9-496a-a019-aab43c351824

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c